Ascendis Pharma Files 6-K for S-8 Registration

Ticker: ASND · Form: 6-K · Filed: Jul 28, 2025 · CIK: 1612042

Sentiment: neutral

Topics: sec-filing, 6-K, registration

Related Tickers: ASND

TL;DR

Ascendis Pharma (ASND) filed a 6-K on 7/28/25, referencing S-8 filings. Standard compliance.

AI Summary

Ascendis Pharma A/S filed a Form 6-K on July 28, 2025, to report information as a foreign private issuer. The filing is related to their registration statements on Form S-8, specifically referencing Registration Numbers 333-203040 and 333-2108. The company is incorporated in G7 and its fiscal year ends on December 31.

Why It Matters

This filing indicates ongoing administrative or compliance activities related to Ascendis Pharma's equity compensation plans, which could impact employee stock options and future share dilution.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically impact stock price.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange.

What are the Form S-8 registration numbers mentioned?

The Form S-8 registration numbers mentioned are 333-203040 and 333-2108.

When was this Form 6-K filed?

This Form 6-K was filed on July 28, 2025.

What is Ascendis Pharma A/S's principal executive office address?

Ascendis Pharma A/S's principal executive office is located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.

Does Ascendis Pharma A/S file annual reports under Form 20-F or 40-F?

Ascendis Pharma A/S files annual reports under Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 28, 2025 regarding Ascendis Pharma A/S (ASND).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing